



ASX RELEASE

Volpara Group Signs Highest Value Contract to Date via CRA Health

Wellington, NZ, 12 March 2021: [Volpara Health Technologies](#) ("Volpara," "the Group," or "the Company"; ASX: VHT), a health technology software company whose integrated breast care platform assists in the delivery of personalised patient care, today advises that it has signed its highest value contract to date via its recently acquired CRA Health subsidiary.

The contract, worth over US\$400,000 per year of Annual Recurring Revenue (ARR), covers the provision of breast cancer risk scores to a large Indiana-based organization that has sites across more than 20 states and runs a major Electronic Health Record system, which makes the deployment and implementation very cost effective.

Volpara Group CEO Dr Ralph Highnam said of the deal: "We are very pleased to announce that CRA Health has signed up a major US health system with significant ARR associated with it. Whilst we would not normally announce individual deals, this is the Volpara Group's highest value contract signed to date. Not only does it enable us to help many more women across the United States benefit from early cancer detection, but it also sets us up for future sales of additional products to this organization. Further, the contract is validation of the decision to purchase CRA Health and validation that the world is rapidly moving towards personalised breast care, which includes analysis of risk and genetics."

Authorisation & Additional Information

This announcement was authorised by the Dr Ralph Highnam, Group CEO of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparahealth.com
t: +64 21 149 0541

Trevor Chappell
WE Communications
WE-AUVolpara@we-worldwide.com
t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020 and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software) and CRA Health LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com